Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Amgen buys back product rights from GSK

Amgen buys back product rights from GSK

review in Europe, as well as oncolytic virus therapy Imlygic (talimogene laherparepvec), approved in the US in October.

Latest news

  • Amgen gets FDA nod for virus-based melanoma therapy Amgen gets FDA nod for virus-based melanoma therapy

    Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and destroy melanoma lesions in the skin and lymph nodes that cannot

  • CHMP October meeting gives recommendations for Pfizer and MSD CHMP October meeting gives recommendations for Pfizer and MSD

    Amgen's Imlygic (talimogene laherparepvec) is seeking an indication for the treatment of adults with unresectable melanoma that is regionally or distantly metastic (stage IIIB, IIIC and IVM1a).

  • Amgen and Merck to expand cancer collaboration Amgen and Merck to expand cancer collaboration

    Amgen and Merck have expanded their collaboration to evaluate the efficacy and safety of Amgen's talimogene laherparepvec in combination with Merck's Keytruda. ... Talimogene laherparepvec and Keytruda are designed to result in anti-tumour immune

  • FDA gives priority review for Keytruda in lung cancer FDA gives priority review for Keytruda in lung cancer

    Earlier, the company also signed an expanded deal to test Amgen's oncolytic virus therapy talimogene laherparepvec with Keytruda in head and neck cancer.

  • AZ and BMS earn ASCO plaudits AZ and BMS earn ASCO plaudits

    Big pharma deals. Meanwhile, Amgen has announced a tie-up with Roche w ith the two firms' investigational medicines talimogene laherparepvec and atezolizumab. ... Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Free Thinking: From promise to practice: immuno-oncology in action
...
Video: Syndicated patient record data
Track the global market in real time...
Video: Patient level prescribing decisions
...

Infographics